AbbVie Inc. (ABBV)
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.
AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Stocks Retirees Should Absolutely Love
Priorities change as you enter new seasons of life. That's especially true for your retirement years.
Jim Cramer Says To Buy These 3 Dividend Stocks ASAP
Jim Cramer likes these dividend stocks for 2025. All three dividend stocks are solid financially and pay good yields.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie Inc. NYSE: ABBV stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net revenue of $15.42 billion, beating expectations for $14.93 billion.
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie Stock Pops After Earnings Beat and Guidance Raised
Second quarter EPS came in at $2.97 on revenue of $15.4 billion, beating analysts expectations.
